Marinus Pharmaceuticals’ (MRNS) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Friday morning, Benzinga reports.

Several other equities research analysts have also recently commented on the company. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday. JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday. StockNews.com raised Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 4th. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Finally, Royal Bank of Canada lowered their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research note on Friday. Eight equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $6.07.

Marinus Pharmaceuticals Price Performance

NASDAQ:MRNS opened at $0.41 on Friday. Marinus Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $11.26. The stock’s 50-day moving average is $1.54 and its two-hundred day moving average is $1.56. The stock has a market cap of $22.31 million, a PE ratio of -0.15 and a beta of 1.14.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The business had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. During the same period last year, the firm earned ($0.61) EPS. On average, equities research analysts anticipate that Marinus Pharmaceuticals will post -1.93 earnings per share for the current year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new stake in Marinus Pharmaceuticals during the second quarter worth approximately $727,000. Wellington Management Group LLP boosted its position in shares of Marinus Pharmaceuticals by 54.8% in the fourth quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock valued at $2,623,000 after acquiring an additional 85,455 shares during the period. Vanguard Group Inc. boosted its position in shares of Marinus Pharmaceuticals by 5.0% in the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after acquiring an additional 132,689 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at approximately $813,000. Finally, Hussman Strategic Advisors Inc. boosted its position in shares of Marinus Pharmaceuticals by 14.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 10,500 shares during the period. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.